{
    "clinical_study": {
        "@rank": "143093", 
        "arm_group": [
            {
                "arm_group_label": "Standard Dosing Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard Dosing Group will receive intravitreal injections of 0.3mg. ranibizumab at baseline, week 4 and 8 )sham injections at week 2 and 6).  After week 8 retreatment will be given monthly if edema is greater than 290um or ETDRS visual acuity score <83"
            }, 
            {
                "arm_group_label": "Frequent dosing group", 
                "arm_group_type": "Experimental", 
                "description": "Frequent dosing subjects will be evaluated and treated every two weeks through week 8 with intravitreal injection of 0.3mg ranibizumab.  Subjects will then be evaluated monthly through week 24 and will receive treatment with ranibiumab based on residual edema and visual acuity"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators would like to investigate the efficacy of more frequent treatment with\n      Lucentis for subjects with persistent diabetic macular edema despite standard dosing\n      regimen."
        }, 
        "brief_title": "Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Persistent Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, subject masked, phase II study of intravitreally administered\n      ranibizumab in subjects with persistent diabetic macular edema. Persistent diabetic macular\n      edema is defined as subjects who still have central subfield thickness on SD-OCT of greater\n      than 320 microns after having received at least 3 previous doses of AntiVEGF therapy in the\n      past 5 months.  Consented, enrolled subjects will be randomized into two subgroups:  (1)\n      standard dosing of monthly 0.3mg ranibizumab or (2) 0.3mg ranibizumab given 2 weeks apart\n      for 5 doses followed by monthly dosing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects will be eligible if the following criteria are met:\n\n          -  Ability to provide written informed consent and comply with study assessments for the\n             full duration of the study\n\n          -  Age >18 years\n\n          -  Diagnosis of Type 1 or Type 2 diabetes\n\n          -  BCVA score using the ETDRS method of >24 and <78 in the study eye at the screening\n             visit\n\n          -  3 or more intravitreal injections of AntiVEGF over the 5 months prior to screening\n\n          -  Presence of diabetic macular edema defined as SD-OCT CST >320 microns on spectral\n             domain machine\n\n        Exclusion Criteria:\n\n          -  Subjects who meet any of the following criteria will be excluded from this study:\n\n               -  Anti-VEGF treatment in the study eye within 3 weeks prior to  screening\n\n               -  Intravitreal Ozurdex treatment in the study eye within 12 weeks prior to\n                  screening\n\n               -  Intravitreal steroid treatment in the study eye within 8 weeks prior to\n                  screening\n\n               -  PRP or focal laser in the study eye within 4 months prior to screening\n\n               -  Active iris neovascularization in the study eye\n\n               -  Any ocular condition in the study eye that, in the opinion of the investigator,\n                  is severe enough to compromise the study result.\n\n               -  History of cataract surgery in the study eye within 3 months prior to screening\n                  visit\n\n               -  Uncontrolled systemic disease\n\n               -  Current enrollment in an investigational drug study or participation in such a\n                  study within 30 days prior to the screening visit\n\n               -  Female patients who are pregnant, nursing or planning a pregnancy or who are of\n                  childbearing potential and not using a reliable means of contraception.\n\n               -  Any condition or reason (including inability to read ETDRS chart or language\n                  barrier) that precludes the patient's ability to comply with study requirements\n                  including completion of the study.\n\n               -  Known allergy, hypersensitivity or contraindication to the study medications,\n                  its components, fluorescein or povidone iodine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127684", 
            "org_study_id": "ML29381"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard Dosing Group", 
                "description": "ranibizumab 0.3mg intravitreally monthly", 
                "intervention_name": "ranibizumab", 
                "intervention_type": "Drug", 
                "other_name": "Lucentis"
            }, 
            {
                "arm_group_label": "Frequent dosing group", 
                "description": "ranibizumab given every 2 weeks for 8 weeks then monthly as needed", 
                "intervention_name": "ranibizumab", 
                "intervention_type": "Drug", 
                "other_name": "Lucentis"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "diabetic macular edema", 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "contact": {
                "email": "Cari.novak@gmail.com", 
                "last_name": "Cari Novak", 
                "phone": "317-805-4596"
            }, 
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46290"
                }, 
                "name": "Raj K Maturi MD"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard AntiVEGF Dosing", 
        "overall_official": {
            "affiliation": "Raj K. maturi MD PC", 
            "last_name": "Raj K Maturi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "mean change in optical coherence topography central subfield thickness at 12 weeks and 24 weeks after randomization", 
            "measure": "mean change in optical coherence topography central subfield thickness at 12 weeks and 24 weeks after randomization", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Maturi, Raj K., M.D., P.C.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Maturi, Raj K., M.D., P.C.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}